11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial von Cameron, David, Prof, Piccart-Gebhart, Martine J, PhD, Gelber, Richard D, PhD, Procter, Marion, PhD, Goldhirsch, Aron, MD, de Azambuja, Evandro, MD, Castro, Gilberto, MD, Untch, Michael, MD, Smith, Ian, MD, Gianni, Luca, MD, Baselga, Jose, MD, Al-Sakaff, Nedal, PhD, Lauer, Sabine, PhD, McFadden, Eleanor, MA, Leyland-Jones, Brian, MBBS, Bell, Richard, MBBS, Dowsett, Mitch, PhD, Jackisch, Christian, MD

Volltext

Mutation Matters in Precision Medicine: A Future to Believe In von Nandini, Dey, Casey, Williams, Brian, Leyland-Jones, Pradip, De

Volltext

Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Central Nervous System Metastases von Brian Leyland-Jones

Volltext

PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials von Dey, Nandini, De, Pradip, Leyland-Jones, Brian

Volltext

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti‐HER2 targeted therapies von Ross, Jeffrey S., Gay, Laurie M., Wang, Kai, Ali, Siraj M., Chumsri, Saranya, Elvin, Julia A., Bose, Ron, Vergilio, Jo‐Anne, Suh, James, Yelensky, Roman, Lipson, Doron, Chmielecki, Juliann, Waintraub, Stanley, Leyland‐Jones, Brian, Miller, Vincent A., Stephens, Philip J.

Volltext

Doubling Down on the PI3K-AKT-mTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness von De, Pradip, Sun, Yuling, Carlson, Jennifer H, Friedman, Lori S, Leyland-Jones, Brian R, Dey, Nandini

Volltext

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study von Sicklick, Jason K., Kato, Shumei, Okamura, Ryosuke, Schwaederle, Maria, Hahn, Michael E., Williams, Casey B., De, Pradip, Krie, Amy, Piccioni, David E., Miller, Vincent A., Ross, Jeffrey S., Benson, Adam, Webster, Jennifer, Stephens, Philip J., Lee, J. Jack, Fanta, Paul T., Lippman, Scott M., Leyland-Jones, Brian, Kurzrock, Razelle

Volltext

A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non‐small cell lung cancer von Solomon, Benjamin, Callejo, Ana, Bar, Jair, Berchem, Guy, Bazhenova, Lyudmila, Saintigny, Pierre, Wunder, Fanny, Raynaud, Jacques, Girard, Nicolas, Lee, J. Jack, Sulaiman, Raed, Prouse, Bruce, Bresson, Catherine, Ventura, Hila, Magidi, Shai, Rubin, Eitan, Young, Brandon, Onn, Amir, Leyland‐Jones, Brian, Schilsky, Richard L., Lazar, Vladimir, Felip, Enriqueta, Kurzrock, Razelle

Volltext

Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500 von Smerage, Jeffrey B, Barlow, William E, Hortobagyi, Gabriel N, Winer, Eric P, Leyland-Jones, Brian, Srkalovic, Gordan, Tejwani, Sheela, Schott, Anne F, O'Rourke, Mark A, Lew, Danika L, Doyle, Gerald V, Gralow, Julie R, Livingston, Robert B, Hayes, Daniel F

Volltext

Protein-Coding and MicroRNA Biomarkers of Recurrence of Prostate Cancer Following Radical Prostatectomy von Long, Qi, Johnson, Brent A, Osunkoya, Adeboye O, Lai, Yu-Heng, Zhou, Wei, Abramovitz, Mark, Xia, Mingjing, Bouzyk, Mark B, Nam, Robert K, Sugar, Linda, Stanimirovic, Aleksandra, Williams, Daron J, Leyland-Jones, Brian R, Seth, Arun K, Petros, John A, Moreno, Carlos S

Volltext

Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors von Dey, Nandini, De, Pradip, Brian, Leyland-Jones

Volltext

Wnt signaling in triple negative breast cancer is associated with metastasis von Dey, Nandini, Barwick, Benjamin G, Moreno, Carlos S, Ordanic-Kodani, Maja, Chen, Zhengjia, Oprea-Ilies, Gabriella, Tang, Weining, Catzavelos, Charles, Kerstann, Kimberly F, Sledge, Jr, George W, Abramovitz, Mark, Bouzyk, Mark, De, Pradip, Leyland-Jones, Brian R

Volltext

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial von Goldhirsch, Aron, Prof, Gelber, Richard D, Prof, Piccart-Gebhart, Martine J, Prof, de Azambuja, Evandro, MD, Procter, Marion, MSci, Suter, Thomas M, Prof, Jackisch, Christian, Prof, Cameron, David, Prof, Weber, Harald A, MD, Heinzmann, Dominik, PhD, Lago, Lissandra Dal, MD, McFadden, Eleanor, MA, Dowsett, Mitch, Prof, Untch, Michael, Prof, Gianni, Luca, MD, Bell, Richard, Prof, Köhne, Claus-Henning, Prof, Vindevoghel, Anita, MD, Andersson, Michael, MD, Brunt, A Murray, MD, Otero-Reyes, Douglas, MD, Song, Santai, MD, Smith, Ian, Prof, Leyland-Jones, Brian, PhD, Baselga, Jose, Prof

Volltext

Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis von Willis, Scooter, Villalobos, Victor M, Gevaert, Olivier, Abramovitz, Mark, Williams, Casey, Sikic, Branimir I, Leyland-Jones, Brian

Volltext

Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01) von DE AZAMBUJA, Evandro, PROCTER, Marion J, JACKISCH, Christian, CAMERON, David A, BELL, Richard, LEYLAND-JONES, Brian, DOWSETT, Mitch, GELBER, Richard D, PICCART-GEBHART, Martine J, SUTER, Thomas M, VAN VELDHUISEN, Dirk J, AGBOR-TARH, Dominique, METZGER, Otto, STEINSEIFER, Jutta, UNTCH, Michael, SMITH, Ian E, GIANNI, Luca, BASELGA, Jose

Volltext

RET rearrangements are actionable alterations in breast cancer von Paratala, Bhavna S., Chung, Jon H., Williams, Casey B., Yilmazel, Bahar, Petrosky, Whitney, Williams, Kirstin, Schrock, Alexa B., Gay, Laurie M., Lee, Ellen, Dolfi, Sonia C., Pham, Kien, Lin, Stephanie, Yao, Ming, Kulkarni, Atul, DiClemente, Frances, Liu, Chen, Rodriguez-Rodriguez, Lorna, Ganesan, Shridar, Ross, Jeffrey S., Ali, Siraj M., Leyland-Jones, Brian, Hirshfield, Kim M.

Volltext

Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer von Pierobon, Mariaelena, Ramos, Corinne, Wong, Shukmei, Hodge, K Alex, Aldrich, Jessica, Byron, Sara, Anthony, Stephen P, Robert, Nicholas J, Northfelt, Donald W, Jahanzeb, Mohammad, Vocila, Linda, Wulfkuhle, Julia, Gambara, Guido, Gallagher, Rosa I, Dunetz, Bryant, Hoke, Nicholas, Dong, Ting, Craig, David W, Cristofanilli, Massimo, Leyland-Jones, Brian, Liotta, Lance A, O'Shaughnessy, Joyce A, Carpten, John D, Petricoin, Emanuel F

Volltext

Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study von Sicklick, Jason K, Kato, Shumei, Okamura, Ryosuke, Patel, Hitendra, Nikanjam, Mina, Fanta, Paul T, Hahn, Michael E, De, Pradip, Williams, Casey, Guido, Jessica, Solomon, Benjamin M, McKay, Rana R, Krie, Amy, Boles, Sarah G, Ross, Jeffrey S, Lee, J Jack, Leyland-Jones, Brian, Lippman, Scott M, Kurzrock, Razelle

Volltext

Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner von Dey, Nandini, Young, Brandon, Abramovitz, Mark, Bouzyk, Mark, Barwick, Benjamin, De, Pradip, Leyland-Jones, Brian

Volltext

Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer von ROBERT, Nicholas, LEYLAND-JONES, Brian, ALBAIN, Kathy, MCCULLOUGH, Cecelia, FUCHS, Lea, SLAMON, Dennis, ASMAR, Lina, BELT, Robert, ILEGBODU, Des, LOESCH, David, RAJU, Robert, VALENTINE, Elizabeth, SAYRE, Robert, COBLEIGH, Melody

Volltext